{"disease":{"id":"epstein-barr-virus-infection","name":"epstein barr virus infection"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT03546101","title":"Early Detection of Epstein-Barr Virus Related Disease.","phase":"","overall_status":"COMPLETED","enrollment_count":1527,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05164094","title":"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":867,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT06908096","title":"Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05831111","title":"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":482,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT05305040","title":"Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":451,"lead_sponsor_name":"AlloVir","has_results":true},{"nct_id":"NCT06002802","title":"Study on Infectious Mononucleosis in Munich","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT01972035","title":"ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"University of Minnesota","has_results":true},{"nct_id":"NCT05841342","title":"Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":128,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT04989491","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT07256431","title":"Environmental Risk Factors in Multiple Sclerosis Development: Epidemiological Study of EBV Infection and Vitamin D Deficiency in RIS Patients","phase":"","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT03374566","title":"Immunodeficiency for Severe Epstein-Barr Virus Infection","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT04645147","title":"Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":83,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT07381738","title":"Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06554197","title":"Evaluation of CMV/EBV-CMI in Haploid HSCT","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT00070785","title":"Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT00005924","title":"Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus","phase":"","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03258567","title":"Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06789159","title":"A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT05384743","title":"Rituximab Monotherapy for EBV-HLH and CAEBV","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07133776","title":"Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT04693637","title":"Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"AlloVir","has_results":true},{"nct_id":"NCT06909110","title":"Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Jessie L. Alexander","has_results":false},{"nct_id":"NCT06027879","title":"Anti-viral T-cell Therapy by Gamma Capture","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":25,"lead_sponsor_name":"Paul Szabolcs","has_results":false},{"nct_id":"NCT05683834","title":"Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT01094405","title":"Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03266653","title":"EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"New York Medical College","has_results":false},{"nct_id":"NCT01805037","title":"Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT07368634","title":"Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Daihong Liu","has_results":false},{"nct_id":"NCT05532826","title":"Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT","phase":"NA","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT06491719","title":"A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT03769467","title":"Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Atara Biotherapeutics","has_results":true},{"nct_id":"NCT04507477","title":"Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT05236764","title":"Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3,"lead_sponsor_name":"Baylor College of Medicine","has_results":true},{"nct_id":"NCT07104591","title":"TETRAVI Expanded Access Program","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT02822495","title":"Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false}],"total":37},"guidelines":[],"source":"Drug Landscape verified database"}